- Home
- OGI vs IMMP Comparison
OGI vs IMMP Comparison
Compare OGI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- IMMP
- Stock Information
- Founded
- OGI 2013
- IMMP 1987
- Country
- OGI Canada
- IMMP Australia
- Employees
- OGI N/A
- IMMP N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- IMMP Health Care
- Exchange
- OGI Nasdaq
- IMMP Nasdaq
- Market Cap
- OGI 234.5M
- IMMP 251.8M
- IPO Year
- OGI N/A
- IMMP N/A
- Fundamental
- Price
- OGI $1.77
- IMMP $2.03
- Analyst Decision
- OGI
- IMMP Buy
- Analyst Count
- OGI 0
- IMMP 1
- Target Price
- OGI N/A
- IMMP $7.00
- AVG Volume (30 Days)
- OGI 863.0K
- IMMP 197.6K
- Earning Date
- OGI 08-13-2025
- IMMP 10-10-2025
- Dividend Yield
- OGI N/A
- IMMP N/A
- EPS Growth
- OGI N/A
- IMMP N/A
- EPS
- OGI 0.05
- IMMP N/A
- Revenue
- OGI $164,107,753.00
- IMMP $3,306,742.00
- Revenue This Year
- OGI $59.31
- IMMP $16.82
- Revenue Next Year
- OGI $15.12
- IMMP N/A
- P/E Ratio
- OGI $41.54
- IMMP N/A
- Revenue Growth
- OGI 50.01
- IMMP 31.28
- 52 Week Low
- OGI $0.85
- IMMP $1.32
- 52 Week High
- OGI $2.08
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- OGI 46.32
- IMMP 59.70
- Support Level
- OGI $1.67
- IMMP $1.96
- Resistance Level
- OGI $2.05
- IMMP $2.17
- Average True Range (ATR)
- OGI 0.09
- IMMP 0.12
- MACD
- OGI -0.03
- IMMP -0.01
- Stochastic Oscillator
- OGI 20.41
- IMMP 33.33
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.